Alkem

{{ Form::open(['url' => '#', 'name' => 'validateForm', 'id' => 'validateForm', 'enctype' => 'multipart/form-data']) }} @csrf

Back

DEN

Comprehensive Retrospective Analysis of the Efficacy, Safety, and Bone Health Outcomes in Breast Cancer Patients Undergoing Adjuvant Treatment with Aromatase Inhibitors and Denosumab: A Multicenter Observational Study

Patient No *

Patient Initials *

Date of Enrollment *

Demographic Information

Age (in Years) *

Gender *

Male Female Other

Menopausal Status *

Pre Post Peri

Ethnicity *

Breast Cancer Characteristics

Cancer Stage *

0 I II III IV

Hormone Receptor Status

Estrogen Receptor (ER) *

Positive Negative

Progesterone Receptor (PR) *

Positive Negative

HER2 Status *

Positive Negative Unknown

Treatment History

Type and Duration of Aromatase Inhibitor (AI) Therapy

Drug Name *

Start Date *

End Date *

Duration of Denosumab Therapy *

Adherence to Denosumab Therapy *

Yes No Partially

Adherence to Calcium Supplementation *

Yes No Partially

Adherence to Vitamin D Supplementation *

Yes No Partially

Bone Health Parameters

Baseline Bone Mineral Density (BMD) (g/cm²)

Bone Mineral Density (BMD) at 12 Months (g/cm²)

C-terminal Telopeptide of Type 1 Collagen (CTx) Levels at Baseline: (ng/mL) (If available)

Adverse Events

Fractures *

Yes No

Osteoporosis Diagnosis *

Yes No

Other adverse events *

Yes No

Concomitant Medications

Other Medications Used *

Including dose	Duration	Specify

Additional Comments/Notes: (Any additional relevant information)

Data Collection Date: (Date when the data was collected)*

@include('user.footer')